The prevailing perception-that most chronic pancreatitis patients (CP) are alcoholics, have chronic pain, are narcotic seeking; and, there is little to offer to them in terms of treatment is incorrect. CP is a complex disease caused not solely from heavy alcohol consumption; and, it has highly variable clinical symptomatology and disease course. Fellows rotating on inpatient pancreatobiliary consult service and outpatient clinic are frequently amazed at the nuances of clinical practice, and our ability to help a large fraction of these patients with sustained improvement in symptoms and quality of life.
The Red SecTion
The prevailing perception-that most chronic pancreatitis patients (CP) are alcoholics, have chronic pain, are narcotic seeking; and, there is little to offer to them in terms of treatment is incorrect. CP is a complex disease caused not solely from heavy alcohol consumption; and, it has highly variable clinical symptomatology and disease course. Fellows rotating on inpatient pancreatobiliary consult service and outpatient clinic are frequently amazed at the nuances of clinical practice, and our ability to help a large fraction of these patients with sustained improvement in symptoms and quality of life.
Making a diagnosis
Obtaining a good medical history cannot be overemphasized. Eliciting a history of typical pancreatic pain, prior history of documented attack(s) of acute pancreatitis (AP), male infertility, family history of pancreatitis or pancreatic cancer, clinical symptoms of steatorrhea, and diabetes are all helpful adjuncts. Typically, pancreatitis pain is described by patients as a dull aching or boring type sensation located in the upper abdomen, often epigastrium, which may worsen after food intake and radiate to the back. Presence, severity and temporal nature of pain in CP can be highly variable between patients and during the clinical course of an individual patient [1] . Mild elevations in serum pancreatic enzymes in the right clinical setting may also be helpful. For evaluation, we obtain a contrast-enhanced pancreas protocol computed tomography (CT) scan, and if needed, a contrast-enhanced magnetic resonance imaging (MRI) with secretin-stimulated cholangiopancreatography (MRCP) to assess the pancreatic parenchyma, ductal system, and presence and type of local complications. A negative CT and MRI/MRCP does not necessarily exclude the diagnosis, as definitive changes on imaging could lag behind clinical symptoms for a variable time. In a subset of patients with convincing history but normal cross-sectional studies, we perform an endoscopic ultrasound (EUS) to further assess for morphological changes. We are cognizant that a normal or minimally abnormal EUS does not exclude or diagnose CP, and the confounding effect of several factors (e.g., age, alcohol, tobacco, and diabetes) on parenchymal and ductal changes must also be considered [2, 3] . We do not routinely use secretinstimulated pancreatic function testing in clinical practice, as its positive predictive value is suboptimal [4] , and may not affect decision making.
assessing etiology
We obtain a careful history of alcohol consumption in all patients-while a history of heavy drinking (≥5 drinks a day on average) is highly suggestive of alcohol etiology [5] , we consider regular consumption of lower amounts of alcohol as a potential co-factor. We ask about smoking history, as it increases the risk of pancreatitis, independent of alcohol consumption [5] . In the absence of significant alcohol use, we evaluate for other potential etiologies-hypercalcemia, hyperlipidemia, celiac disease, known genetic abnormalities [6] associated with pancreatitis (mutations in CFTR, PRSS1, SPINK1, and CTRC genes), and autoimmune pancreatitis. An MRI/MRCP with secretin helps to evaluate for ductal abnormalities such as pancreas divisum, which we view as a potential disease-modifying factor. Personal and family history mentioned above can provide important clues.
assessing syMptoM burden and trajectory
Knowledge of the natural history is critical not only for assessing symptom burden and trajectory but for determining the response to treatment. This includes categorizing the presence of waxing and waning abdominal pain symptoms interspersed with episode(s) of AP, progressive increase in morphological changes, and loss of exocrine and endocrine function, and healthcare utilization. A recent large cross-sectional analysis found constant pain to be reported by ~50% patients, and roughly the same fraction used narcotic medications, intermittently or constantly [1] . It is also important to recognize that the morphological appearance of the pancreas does not always correlate with clinical symptoms or gland dysfunction [1] .
We pay great attention to assessing symptom burden and disease trajectory to guide management decisions. The key is to balance between conservative management or aggressive therapies (endoscopic therapy, surgery)-for the latter, you do not want to act too early but not want to wait for too long. Furthermore, you cannot determine effectiveness of treatment without a solid recognition of the pre-treatment disease burden.
Managing syMptoMs

Abdominal pain and AP
We manage AP in a patient with CP in a standard fashion based on severity.
In a symptomatic patient, cross-sectional imaging (CT scan ± MRI/MRCP ± EUS) provides the primary branchpoint for management by stratifying patients into those with obstructive (pancreatic ductal stones/strictures with upstream dilatation) vs. non-obstructive disease (Fig. 1) .
If applicable, we counsel all patients for abstinence from alcohol and tobacco. In a patient with low burden of pain symptoms, irrespective of morphology, intermittent use of pain medications may be all that is needed. In patients with non-obstructive disease (and those with obstructive disease in whom we chose an initial conservative route) and a high burden of symptoms, we routinely seek assistance from colleagues in pain medicine and psychology/psychiatry for assistance in the management of pain and consideration of alternative strategies (e.g. cognitive behavioral therapy). We may choose to prescribe pancreatic enzyme replacement therapy (PERT) in adequate doses to achieve negative feedback of pancreatic secretion recognizing that convincing data for pain relief with this approach are limited [7] . Similarly, we use antioxidants for pain management selectively [8] .
In patients with obstructive disease and high symptoms burden, we discuss options of endoscopic or surgical treatments depending on ongoing alcohol and tobacco consumption, location of and burden of stricture(s) and calcifications. Patient compliance is critical, as a course of endotherapy could involve several sessions spread over 6-12 months. We consider endoscopic approach with or without extracorporeal shockwave lithotripsy in patients with proximal disease (i.e. head and proximal body) and low/moderate stone burden, shorter duration of symptoms and local complications (e.g., pseudocysts) amenable to such therapy. In select patients, such as those with an inflammatory mass in the pancreatic head, we have a low threshold to provide nasoenteral nutrition and use endotherapy as a bridge to surgery to allow for resolution of inflammatory changes prior to surgical intervention [9] .
We consider a total pancreatectomy with islet cell transplantation (TPIAT) in patients with high symptoms burden who are not diabetic or have borderline diabetes. At our center, typically, these are patients with idiopathic or genetic pancreatitis. The decision for TPIAT is taken after formal evaluation and discussion by a multidisciplinary committee. Since prior surgery and multiple endoscopic therapy sessions are associated with poor islet yield and outcomes [10] , in suitable candidates, a discussion of TPIAT occurs prior to embarking on such treatments.
Pancreatic insufficiency, diabetes and bone health
We assess exocrine insufficiency (fecal elastase), diabetes (fasting glucose, hemoglobin A1c), bone health (calcium, vitamin D), vitamin B12, calcium and liver functions at initial evaluation. More recently, we have adopted DXA scanning in the routine care of these patients. We treat exocrine insufficiency by appropriate dosing with oral PERT, and seek assistance of primary care/endocrinology to manage diabetes and bone health issues. We counsel patients to avoid antidiabetic medications with suspected link with pancreatitis (e.g., GLP-agonists, DPP4-inhibitors). Abstinence from alcohol and smoking is recommended in all patients, as applicable. Pain management includes analgesics (acetaminophen, non-steroidal anti-inflammatory agents, narcotics), adjunctive treatment (tricyclic antidepressants, gabapentinoids, SSRIs, SNRIs), and other strategies (e.g. cognitive behavioral therapy) depending on pain severity and temporal nature. In patients with constant/frequent symptoms we seek assistance with pain clinic, psychology and psychiatry. 2 Refers to obstructive disease due to stones and/or strictures in the pancreatic duct. 3 Indication for ET typically is presence of ductal stones and/or stricture in the head/body of the pancreas. ET is used as a "bridge to surgery" in specific situations, e.g. an inflammatory mass in the head of the pancreas, to allow for resolution of inflammation in the pancreas and peripancreatic area. 4 Indications for surgery include failed ET, heavy stone burden, especially in the body/ tail region, and an inflammatory mass in the head of the pancreas. 3, 4 In suitable candidates, a discussion of total pancreatectomy with islet autotransplantation (TPIAT) occurs prior to consideration of ET and surgery. 5 In a suitable candidate, surgery in this situation would typically be a TPIAT. 
Follow up
We follow stable patients yearly. We perform assessment for diabetes every 6 months, other tests mentioned above yearly, and DXA scans every 3 years. If case a stable patient becomes symptomatic, depending on symptoms, we perform a cross-sectional imaging to evaluate for disease progression and/or local complication to guide appropriate management. Patients often ask about the risk of pancreatic cancer -while we acknowledge the increased risk, we discuss limitations in making early diagnosis, its overall low prevalence, and emphasize the importance of abstaining from smoking and drinking as the best possible preventative strategies currently.
Final thoughts
Evaluation and management of CP can be challenging. We believe and practice in a multidisciplinary approach in managing these patients, and work closely with colleagues from therapeutic endoscopy, pancreatobiliary surgery, abdominal radiology, pain medicine, psychology, psychiatry and nutrition. Such an approach often leads to meaningful improvement in the clinical symptoms and quality of life in these patients. 
